NA-931 / Biomed Industries - LARVOL DELTA

Biomed Industries to Present Four Studies at AAIC 2025 on Breakthrough Alzheimer’s, Rett Syndrome, and Obesity Therapies (Firstwordpharma Press Release) - "Biomed Industries...announced it will present four major scientific papers at the Alzheimer’s Association International Conference (AAIC), taking place July 27–31, 2025, in Toronto, Canada...Featured AAIC 2025 Presentations: 1. The End of the Amyloid Era? Evidence for a Paradigm Shift in the Quest to Treat Alzheimer’s Disease; 2. A Phase 3 Clinical Protocol of NA-831 Combined with Donanemab in Early Alzheimer’s Disease: A Placebo-Controlled, Double-Blind Study; 3. Associations Between Alzheimer’s Disease and Rett Syndrome: Clinical Trials of NA-831 and NA-921; 4. Neuro-Metabolic Link Between Alzheimer’s Disease and Obesity: Clinical Evaluation of NA-831 and NA-931"

Clinical protocol • Trial status • Alzheimer's Disease • CNS Disorders • Obesity

Phase 2 Clinical Trials Of Na-931 To Study Subjects Who Are Obese With At Least One Weight-related Comorbid Condition (ENDO 2025) - "The topline results of the Phase 2 of NA-931 showed its potential as a first-in-class oral quadruple receptor agonist for weight loss, with excellent safety and efficacy. The Company is advancing NA-931 to Phase 3 trials."

Clinical • Late-breaking abstract • P2 data • Genetic Disorders • Obesity • IGF1

Phase 2 clinical trials of NA-931 to study subjects who are obese with at least one weight-related comorbid condition (EASD 2025) - P2 | "The topline results of the Phase 2 trial support NA-931 as a promising first-in-class oral quadruple receptor agonist for weight loss, demonstrating excellent efficacy and safety. The company is advancing NA-931 to Phase 3 trials."

Clinical • P2 data • Diabetes • Metabolic Disorders • Obesity • Pancreatitis • IGF1

Association between Alzheimer's disease and obesity: clinical trials of NA-831 for AD and clinical trials of NA-931 for obesity (EASD 2025) - P2 | "The clinical findings of NA-831 and NA-931 suggest a potential link between Alzheimer's disease, diabetes, and obesity. However, further research is needed to determine whether this association is causal."

Clinical • Diabetes • Metabolic Disorders • Obesity • IGF1

Phase 2 Clinical Trials of NA-931 to Study Subjects Who Are Obese with at Least One Weight-Related Comorbid Condition (ADA 2025) - P2 | "The topline results of the Phase 2 of NA-931 showed its potential as a first-in-class oral quadruple receptor agonist for weight loss, with excellent safety and efficacy. The Company is advancing NA-931 to Phase 3 trials."

Clinical • Late-breaking abstract • P2 data • Metabolic Disorders • Obesity • IGF1

Associations between Alzheimer's Disease (AD) and Obesity—Clinical Trials of NA-813 for AD and NA-931 for Obesity (ADA 2025) - P2 | "Associations of Alzheimer's disease and diabetes obesity have been suggested with clinical results of NA-831 and NA-931. However, whether this association is causal requires further evaluation."

Clinical • Late-breaking abstract • Diabetes • Metabolic Disorders • Obesity • IGF1

NA-931, a Novel Quadruple IGF-1-1, GLP-1, GIP, and Glucagon Receptor Agonist Reduces Body Weight without Muscle Loss (ADA 2025) - "We are conducting a Phase 2 trial with the oral formulation of NA-931 for the possible treatment of obesity."

Metabolic Disorders • Obesity • IGF1

Phase 2 Trials of NA-931 to Study Subjects Who Are Obese With at Least One Weight-related Comorbid Condition (clinicaltrials.gov) - P2 | N=126 | Completed | Sponsor: Biomed Industries, Inc. | Recruiting ➔ Completed

Trial completion • Genetic Disorders • Obesity

Biomed Industries, Inc. to Present Phase 2 Results on NA-931—An Oral Alternative to Injectables for Obesity—at ADA 2025 (EIN Presswire) - "Biomed Industries...will present results from its Phase 2 clinical trial of NA-931, a first-in-class oral quadruple receptor agonist for the treatment of obesity, at the 85th Scientific Sessions of the American Diabetes Association (ADA), taking place June 20–23, 2025, in Chicago, Illinois....The Phase 2 study was a randomized, double-blind, placebo-controlled, parallel-arm clinical trial evaluating the safety, tolerability, efficacy, pharmacodynamics, and pharmacokinetics of NA-931 in adults with obesity (BMI ≥30 kg/m²) or who are overweight (BMI ≥27 kg/m²) with at least one weight-related comorbidity."

P2 data • Obesity

Developing Topics. (PubMed, Alzheimers Dement) - "An association of Alzheimer's disease and diabetes obesity has been suggested with clinical results of NA-831 and NA-931. However, whether this association is causal requires further evaluation."

Clinical • Journal • Alzheimer's Disease • CNS Disorders • Diabetes • Genetic Disorders • Hepatology • Metabolic Disorders • Metabolic Dysfunction-Associated Steatohepatitis • Obesity • IGF1

NA-931-200: Safety and Efficacy of NA-931 and Tirzepatide in Adults Who Are Overweight or Obese (clinicaltrials.gov) - P2 | N=224 | Not yet recruiting | Sponsor: Biomed Industries, Inc.

New P2 trial • Genetic Disorders • Obesity

T2DM: Phase 1 to Study Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NA-931 in Obese Participants and Patients With Type 2 Diabetes Mellitus (clinicaltrials.gov) - P1 | N=74 | Completed | Sponsor: Biomed Industries, Inc.

New P1 trial • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus